Country: Ireland
Bahasa: Inggeris
Sumber: HPRA (Health Products Regulatory Authority)
Caspofungin
Demo S.A.
J02AX; J02AX04
Caspofungin
70 milligram(s)
Powder for concentrate for solution for infusion
Product subject to prescription which may not be renewed (A)
Other antimycotics for systemic use; caspofungin
Marketed
2016-09-16
PACKAGE LEAFLET: INFORMATION FOR THE USER CASPOFUNGIN 70 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION CASPOFUNGIN READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, please ask your doctor, nurse or pharmacist. - If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Caspofungin is and what it is used for 2. What you need to know before you are given Caspofungin 3. How will Caspofungin be given to you 4. Possible side effects 5. How to store Caspofungin 6. Contents of the pack and other information 1. WHAT CASPOFUNGIN IS AND WHAT IT IS USED FOR WHAT CASPOFUNGIN IS Caspofungin contains a medicine called caspofungin. This belongs to a group of medicines called anti-fungals. WHAT CASPOFUNGIN IS USED FOR Caspofungin is used to treat the following infections in children, adolescents and adults: • serious fungal infections in your tissues or organs (called ‘invasive candidiasis’). This infection is caused by fungal (yeast) cells called Candida. People who might get this type of infection include those who have just had an operation or those whose immune systems are weak. Fever and chills that do not respond to an antibiotic are the most common signs of this type of infection. • fungal infections in your nose, nasal sinuses or lungs (called ‘invasive aspergillosis’) if other anti-fungal treatments have not worked or have caused side effects. This infection is caused by a mould called Aspergillus. People who might get this type of infection include those having chemotherapy, those who have had a transplant and those whose immune systems are weak. • suspected fungal infections if you have a fever and a low white cell count that have not improved on treatment with an antibiotic. People who are at risk of Baca dokumen lengkap
Health Products Regulatory Authority 01 February 2021 CRN009Y8T Page 1 of 14 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Caspofungin 70mg powder for concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 70 mg caspofungin (as acetate). The concentration of the reconstituted vial will be 7.2 mg/mL. Excipients with known effect Each 70 mg vial contains 50.0 mg of sucrose. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. Before reconstitution, the powder is a white to off-white-compact, powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Treatment of invasive candidiasis inadult or paediatric patients. • Treatment of invasive aspergillosis inadult or paediatric patients who are refractory to or intolerant ofamphotericin B, lipid formulations of amphotericin B and/or itraconazole.Refractoriness is defined as progression of infection or failure to improveafter a minimum of 7 days of prior therapeutic doses of effectiveantifungal therapy. • Empirical therapy for presumed fungalinfections (such as _Candida_ or _Aspergillus_) in febrile, neutropaenicadult or paediatric patients. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Caspofungin should be initiated by a physician experienced in the management of invasive fungal infections. Posology _Adult patients_ A single 70 mg loading dose should be administered on Day-1, followed by 50 mg daily thereafter. In patients weighing more than 80 kg, after the initial 70 mg loading dose, caspofungin 70 mg daily is recommended (see section 5.2). No dosage adjustment is necessary based on gender or race (see section 5.2). _Paediatric population (12 months to 17 years)_ In paediatric patients (12 months to 17 years of age), dosing should be based on the patient's body surface area (see Instructions for Use in Paediatric Patients, Mosteller 1 Formula). For all indications, a single 70-mg/m 2 loading dose (not to exceed an actual dose of 7 Baca dokumen lengkap